Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $24.32 USD
Change Today -0.35 / -1.42%
Volume 228.4K
OMER On Other Exchanges
Symbol
Exchange
NASDAQ GM
Berlin
As of 8:10 PM 04/24/15 All times are local (Market data is delayed by at least 15 minutes).

omeros corp (OMER) Snapshot

Open
$24.58
Previous Close
$24.67
Day High
$25.39
Day Low
$24.28
52 Week High
03/5/15 - $27.64
52 Week Low
05/21/14 - $9.76
Market Cap
919.9M
Average Volume 10 Days
265.8K
EPS TTM
$-2.22
Shares Outstanding
37.8M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for OMEROS CORP (OMER)

omeros corp (OMER) Related Bloomberg News

View More Bloomberg News

omeros corp (OMER) Related Businessweek News

No Related Businessweek News Found

omeros corp (OMER) Details

Omeros Corporation, a biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system. It markets Omidria for use during cataract surgery or intraocular lens, or replacement surgery. The company’s clinical products include OMS721 that is in Phase II clinical trials for the treatment of various complement-mediated disorders, including complement-mediated thrombotic microangiopathies; OMS824, which is in Phase II clinical trials for the treatment of CNS disorders comprising schizophrenia and Huntington's disease; and OMS103 that has completed Phase III clinical trials for use during arthroscopic procedures, such as partial meniscectomy surgery. Its clinical programs also comprise OMS405, which is in Phase II clinical trials for the treatment and prevention of addiction to substances of abuse; and OMS201 that has completed Phase I/II clinical trials for use during urological procedures, such as ureterscopy for removal of ureteral or renal stones. The company’s preclinical programs also comprise OMS527 for the treatment of addiction and compulsive disorders, as well as for movement disorders, such as Parkinson's disease; OMS616 for the control of blood loss during surgery, or resulting from trauma or other hyperfibrinolytic conditions; and OMS906 for the treatment of paroxysmal nocturnal hemoglobinuria and other alternative pathway disorders. In addition, its preclinical products consist of GPR17 for the treatment of demyelinating disorders; G protein-coupled receptor platform for multiple disorders across therapeutic area; and antibody platform for the discovery of monoclonal antibodies. Omeros Corporation was incorporated in 1994 and is based in Seattle, Washington.

103 Employees
Last Reported Date: 03/16/15
Founded in 1994

omeros corp (OMER) Top Compensated Officers

Co-Founder, Chairman, Chief Executive Officer...
Total Annual Compensation: $684.1K
Principal Financial Officer, Chief Accounting...
Total Annual Compensation: $285.0K
Vice President of Patent, General Counsel and...
Total Annual Compensation: $352.6K
Compensation as of Fiscal Year 2014.

omeros corp (OMER) Key Developments

European Regulatory Authority Approves Clinical Investigator's Request for Compassionate Use with Omeros Corporation's OMS721

Omeros Corporation announced that the presiding European regulatory authority has approved the company's investigational product OMS721 for compassionate use. OMS721 is Omeros' lead human monoclonal antibody in its mannan-binding lectin-associated serine protease-2 (MASP-2) program for the treatment of thrombotic microangiopathies (TMAs), including atypical hemolytic uremic syndrome (aHUS). TMAs are a family of rare, debilitating and life-threatening disorders characterized by excessive thrombi (clots) in the microcirculation of the body's organs, most commonly the kidney and brain. The two patients in the compassionate-use study suffer from aHUS and were enrolled in the first cohort of the Phase 2 clinical trial. Based on improvements across markers of disease activity in that cohort, the investigator requested that Omeros continue to provide OMS721 so that the patients could extend their treatments. Following regulatory approval, Omeros was pleased to release shipment of OMS721 to continue treatment of these patients. Omeros' ongoing OMS721 Phase 2 study continues to progress through its dose-ranging phase. The second cohort of patients, which received a higher dose than the first cohort, has now completed treatment. Following a pre-planned data review by internal and external physicians, if the safety data from the second cohort are acceptable, a recommendation will be made to advance as scheduled to a third cohort at an even higher dose. This third cohort could begin dosing before the end of April. Omeros' MASP-2 Program: Omeros controls the worldwide rights to MASP-2 and all therapeutics targeting MASP-2, a novel pro-inflammatory protein target involved in activation of the complement system, which is an important component of the immune system. The complement system plays a role in the inflammatory response and becomes activated as a result of tissue damage or microbial infection. MASP-2 appears to be unique to, and required for the function of, one of the principal complement activation pathways, known as the lectin pathway. Importantly, inhibition of MASP-2 does not appear to interfere with the antibody-dependent classical complement activation pathway, which is a critical component of the acquired immune response to infection, and its abnormal function is associated with a wide range of autoimmune disorders. MASP-2 is generated by the liver and is then released into the circulation. Adult humans who are genetically deficient in one of the proteins that activate MASP-2 do not appear to be detrimentally affected by the deficiency. Therefore, Omeros believes that it may be possible to deliver MASP-2 antibodies systemically and OMS721, its lead MASP-2 antibody, is designed to be self-administered by subcutaneous injection.

Omeros Corporation Announces the U.S. Commercial Launch of Omidria™

Omeros Corporation announced the nationwide commercial availability of Omidria (phenylephrine and ketorolac injection) 1%/0.3%. Omidria is the first and only product approved by the U.S. Food and Drug Administration (FDA) for intraocular administration during cataract surgery and other intraocular lens (IOL) replacement procedures to prevent intraoperative miosis (pupil constriction) and to reduce postoperative ocular pain, providing consistent and predictable management of these problems for ophthalmic surgeons and their patients. A large and growing market, cataract and other IOL replacement procedures are among the most common surgical procedures performed in the U.S. with approximately four million expected in 2015. The nationwide commercial launch of Omidria follows the successful completion of a two-month controlled launch during which the product was made available to a relatively small number of ophthalmic surgeons from across the U.S. to allow for any necessary refinements in distribution, reimbursement and other commercial processes. Feedback from the participating facilities and surgeons, both with respect to clinical efficacy and commercial processes, was uniformly positive. Omidria was granted transitional pass-through status effective January 1, 2015 from the Center for Medicare & Medicaid Services (CMS), the federal agency that administers the Medicare program. Pass-through status allows for separate payment for new drugs and other medical technologies that meet specific clinical-value and cost requirements. Pass-through status for Omidria is expected to remain in effect until December 31, 2017, near which time CMS will evaluate utilization of Omidria and will re-assess its reimbursement status. CMS has set the reimbursement rate for Omidria under Medicare Part B at the product's wholesale acquisition cost (WAC) of $465 plus 6% per single-use vial for the second and third quarters of 2015 after which the rate will be based on average selling price (ASP) plus 6%.

Omeros Corporation Presents at Needham & Company's 14th Annual Healthcare Conference, Apr-14-2015 10:40 AM

Omeros Corporation Presents at Needham & Company's 14th Annual Healthcare Conference, Apr-14-2015 10:40 AM. Venue: Westin Grand Central Hotel, New York, New York, United States. Speakers: Gregory A. Demopulos, Co-Founder, Chairman, Chief Executive Officer and President.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
OMER:US $24.32 USD -0.35

OMER Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for OMER.
View Industry Companies
 

Industry Analysis

OMER

Industry Average

Valuation OMER Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 1,538.7x
Price/Book NM Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales 1,633.2x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact OMEROS CORP, please visit www.omeros.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.